This article is more than 5 years old. Information may no longer be current.

TearClear announces $4.5 million in funding for drop filter technology

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TearClear has completed $4.5 million in Series A financing to advance development of its filter technology, designed to deliver preservative-free drops from preserved multi-dose products, the company announced in a press release.

Visionary Venture Fund and Bluestem Capital led the funding.

In addition, William Link, PhD, has been appointed to the company’s board of directors, the release said.

TearClear’s chemical filter removes benzalkonium chloride (BAK) at the point of instillation, allowing products to be preserved until application.

“BAK has been shown to be a significant cause of a host of adverse events with prolonged use, including ocular discomfort, glaucoma surgery failure, conjunctival inflammation and fibrosis, tear film instability, corneal cytotoxicity, and anterior chamber inflammation,” OSN Chief Medical Editor Richard L. Lindstrom, MD, said in the release. “TearClear’s technology offers a compelling and differentiated approach to eliminating the preservative before delivery while allowing it to preserve sterility within the bottle.”